scholarly article | Q13442814 |
P819 | ADS bibcode | 2012PLoSO...737431S |
P356 | DOI | 10.1371/JOURNAL.PONE.0037431 |
P932 | PMC publication ID | 3360787 |
P698 | PubMed publication ID | 22662154 |
P5875 | ResearchGate publication ID | 225098191 |
P50 | author | Osamu Wada-Hiraike | Q51442500 |
Yuji Ikeda | Q61160840 | ||
Katsutoshi Oda | Q87188097 | ||
Hiroyuki Aburatani | Q87657008 | ||
Kei Kawana | Q87946584 | ||
Kenbun Sone | Q104501400 | ||
Michihiro Tanikawa | Q114421877 | ||
Yuji Taketani | Q115215507 | ||
Yōko Matsumoto | Q125919554 | ||
P2093 | author name string | Frank McCormick | |
Tetsu Yano | |||
Shiro Kozuma | |||
Shunsuke Nakagawa | |||
Aki Miyasaka | |||
Tomoko Kashiyama | |||
Yuichiro Miyamoto | |||
Hiroyuki Kuramoto | |||
Takahiro Koso | |||
Haruko Hiraike | |||
Keiko Shoji | |||
P2860 | cites work | Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 | Q21145847 |
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas | Q24646237 | ||
Targeting the mTOR signaling network for cancer therapy | Q24658334 | ||
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling | Q27851446 | ||
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 | ||
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
TOR signaling in growth and metabolism | Q27860757 | ||
High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
PTEN1 is frequently mutated in primary endometrial carcinomas | Q28250937 | ||
PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 | ||
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma | Q34001234 | ||
Global cancer statistics in the year 2000. | Q34571897 | ||
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group | Q35172203 | ||
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability | Q35275603 | ||
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors | Q35778060 | ||
PTEN-deficient cancers depend on PIK3CB. | Q36861839 | ||
Novel molecular profiles of endometrial cancer-new light through old windows. | Q37025301 | ||
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance | Q37036297 | ||
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation | Q37140110 | ||
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. | Q37177892 | ||
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas | Q37269747 | ||
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis | Q37360125 | ||
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer | Q37376100 | ||
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations | Q37382669 | ||
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. | Q37396608 | ||
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors | Q37765246 | ||
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models | Q39706127 | ||
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. | Q39827794 | ||
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation | Q39933516 | ||
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma | Q40345165 | ||
Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations | Q43041602 | ||
Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination | Q43177478 | ||
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. | Q51761211 | ||
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. | Q51803667 | ||
PTEN mutation spectrum in breast cancers and breast hyperplasia. | Q53300858 | ||
K-ras activation in premalignant and malignant epithelial lesions of the human uterus | Q68003898 | ||
PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas | Q74509230 | ||
Endometrial cancer | Q81833884 | ||
Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway | Q82452891 | ||
Everolimus | Q83011817 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | dactolisib | Q4835503 |
P304 | page(s) | e37431 | |
P577 | publication date | 2012-05-25 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas | |
P478 | volume | 7 |
Q36790208 | A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies |
Q27852958 | A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. |
Q33557916 | Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells |
Q37554263 | Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. |
Q38868621 | Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. |
Q54375657 | Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. |
Q38812141 | Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies |
Q28073246 | Chemoresistance and targeted therapies in ovarian and endometrial cancers |
Q34508976 | Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment |
Q50981985 | Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. |
Q37016570 | Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models |
Q38598081 | Emerging strategies for targeting PI3K in gynecologic cancer |
Q39026766 | Endometrial Carcinoma: Specific Targeted Pathways. |
Q36857470 | Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. |
Q38258712 | Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies |
Q33598001 | Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer |
Q39098938 | HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. |
Q37082531 | In-depth molecular profiling of the biphasic components of uterine carcinosarcomas |
Q54379484 | Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures. |
Q34299944 | Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer |
Q52747351 | MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR. |
Q54377413 | Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer. |
Q38067440 | Molecular pathology of endometrial carcinoma |
Q35940829 | Molecular staging of gynecological cancer: What is the future? |
Q36684551 | New candidate therapeutic agents for endometrial cancer: potential for clinical practice (review). |
Q36980561 | PI3K pathway dependencies in endometrioid endometrial cancer cell lines |
Q38882236 | PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer. |
Q34016861 | PTEN-deficient tumors depend on AKT2 for maintenance and survival |
Q37006856 | Personalized care in uterine cancer. |
Q90654533 | Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer |
Q38185940 | Prognostic biomarkers in endometrial and ovarian carcinoma |
Q38778227 | Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. |
Q37301884 | Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging |
Q37381834 | TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers |
Q57169683 | Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late |
Q39454208 | Targeted endometrial cancer therapy as a future prospect |
Q55220517 | The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies. |
Q51767323 | The Yokohama system for reporting directly sampled endometrial cytology: The quest to develop a standardized terminology. |
Q38890954 | The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition. |
Q41582917 | The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells |
Q27852764 | Therapeutic targeting of cancers with loss of PTEN function |
Q26779980 | Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an update |
Q37649634 | mTOR pathway in colorectal cancer: an update |
Search more.